Buy Retatrutide Canada | Triple Agonist
Janoshik
Batch RETA-CA-26F-10
Buy Retatrutide Canada | Triple Agonist
Triple Receptor Agonist
Reta is a research compound studied in laboratory models for its interaction with metabolic signaling pathways, particularly those related to energy balance and glucose regulation systems. Investigations often focus on its receptor activity, downstream intracellular signaling, and overall effects on metabolic pathway modulation in controlled experimental settings.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
In scientific literature, retatrutide is studied for its interaction with multi-receptor signaling pathways, including GLP-1, GIP, and glucagon receptor systems. Research frameworks examine its role in metabolic signaling processes, insulin-related pathway activity, and energy regulation mechanisms within controlled in vitro and preclinical models.
Third-party tested for purity, ID, quantity.
Retatrutide is a next-generation synthetic peptide evaluated in research focused on triple agonist receptor activity. As a compound engineered to interact with GLP-1, GIP, and glucagon receptor systems, it is studied within experimental models examining receptor-driven signaling pathways and metabolic pathway interaction.
Preclinical and clinical research publications have explored its receptor-binding profile, downstream pathway activation, and multi-receptor signaling dynamics under controlled study conditions.
Retatrutide emerged from ongoing research into incretin-based and glucagon receptor–targeted peptide analogues. It was developed as part of broader investigations into multi-agonist strategies within metabolic and endocrine research frameworks.
Early phase studies documented its simultaneous receptor activity across three distinct hormonal pathways, contributing to its classification as a triple receptor agonist in experimental literature.
Laboratory investigations into retatrutide have focused on its multi-receptor agonist properties and signaling behavior across GLP-1, GIP, and glucagon receptor systems. Research models examine receptor activation dynamics, metabolic signaling pathways, insulin-related pathway interaction, and endocrine regulatory mechanisms under controlled experimental conditions.
4 of the 4 areas below are addressed directly by a paper cited on this page.
GLP-1 receptor activation models
Addressed on this page by Jastreboff 2023, Coskun 2022, Rosenstock 2023. The work appeared in N Engl J Med and Cell Metab. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Jastreboff, A.M. et al. (2023) — Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 389(6):514–526.
- Coskun, T. et al. (2022) — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 34(9):1234–1247.e9.
- Rosenstock, J. et al. (2023) — Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402(10401):529–544.
GIP receptor modulation studies
Addressed on this page by Jastreboff 2023, Coskun 2022, Rosenstock 2023. The work appeared in N Engl J Med and Cell Metab. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Jastreboff, A.M. et al. (2023) — Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 389(6):514–526.
- Coskun, T. et al. (2022) — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 34(9):1234–1247.e9.
- Rosenstock, J. et al. (2023) — Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402(10401):529–544.
Glucagon receptor pathway research
Addressed on this page by Coskun 2022, Rosenstock 2023, Janah 2019. The work appeared in Cell Metab and Lancet. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Coskun, T. et al. (2022) — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 34(9):1234–1247.e9.
- Rosenstock, J. et al. (2023) — Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402(10401):529–544.
- Janah, L. et al. (2019) — Glucagon Receptor Signaling and Glucagon Resistance. Int J Mol Sci 20(13):3314.
Multi-pathway metabolic signaling investigations
Addressed on this page by Finan 2015. The work appeared in Mol Cell Endocrinol. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Finan, B. et al. (2015) — Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol 418 Pt 1:42–54.
The references section of this page cites 5 primary papers published between 2015 and 2023 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Retatrutide, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Retatrutide is also referred to as reta, triple G, the triple agonist, LY3437943.
Widely described online as the strongest weight-loss compound available, with claims of dramatic fat loss beyond what semaglutide or tirzepatide produce.
Retatrutide has published phase 2 trial data reporting body-weight reduction in human participants, and that work is cited on this page — so unlike most compounds in this catalogue, human data does exist for the molecule. Two things do not follow from it. It remains in clinical investigation and is not approved for human use by Health Canada, the FDA or any other agency, so its safety profile is not established. And those trials used pharmaceutical-grade material at defined doses under medical supervision, which is not what is supplied here. Cross-compound "strongest" rankings drawn from separate trials in different populations against different endpoints are not supported by the data.
Described as the most effective compound in the incretin class.
Retatrutide is a triple agonist acting at the GIP, GLP-1 and glucagon receptors, and phase 2 results have been published under its own compound code. It is at an earlier stage of clinical investigation than semaglutide or tirzepatide, and cross-trial comparisons between compounds studied in different populations, at different doses and against different endpoints do not support a ranking. It is not approved for human use by any regulatory agency.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for Retatrutide is per lot, not per product. Across the strengths currently stocked: 50mg lot RETA-CA-26C-01 returned 99.82% purity, 54.93 mg measured, 109.9% of the labelled 50 mg; 10mg lot RETA-CA-26F-10 returned 99.637% purity, 11.76 mg measured, 117.6% of the labelled 10 mg; 20mg lot RETA-CA-26F-20 returned 99.577% purity, 24.68 mg measured, 123.4% of the labelled 20 mg; 40mg lot RETA-CA-26F-40 returned 99.703% purity, 40.23 mg measured, 100.6% of the labelled 40 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is Retatrutide; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Retatrutide, across the strengths stocked they run from 100.6% to 123.4% of label. Both numbers are published for every lot, whichever way they fall.
Each strength of Retatrutide carries its own lot code and its own certificate — RETA-CA-26C-01, RETA-CA-26F-10, RETA-CA-26F-20, RETA-CA-26F-40 are separate tests, not one result applied across the range. The code printed on the vial you receive is the one to match, and matching it is what ties the material in hand to a test that was actually run on it.
Researchers who buy Retatrutide in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
Retatrutide is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 39 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (10mg / Single Vial, 50mg / Single Vial, 20mg / Single Vial, 10mg / 5-Pack, 10mg / 10-Pack, 50mg / 5-Pack, 50mg / 10-Pack, 20mg / 5-Pack, 20mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- Canada Post Xpress, tracked, typically 1–2 business days from Alberta
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains the labeled quantity (10mg, 20mg, or 50mg) of lyophilized retatrutide. Independent third-party analysis verifies purity, identity, and net content per batch.
The vial contains only the lyophilized compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 389(6):514–526.
PubMedLY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 34(9):1234–1247.e9.
PubMedRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402(10401):529–544.
PubMedGlucagon Receptor Signaling and Glucagon Resistance. Int J Mol Sci 20(13):3314.
PubMedEmerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol 418 Pt 1:42–54.
PubMedRelated
You May Also Like
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
$35.00
$40.00
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$70.00
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
$150.00
Pentadecapeptide studied for angiogenesis signaling, tissue repair pathways, and cellular regeneration research
$50.00
$60.00